Figure 2 | Scientific Reports

Figure 2

From: Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway

Figure 2

Amelioration of EAE in melatonin treated mice. Analysis of neurological disability displayed: (a) Dailly clinical score, (b) Moving average of the daily clinical score, (c) AUC of the daily clinical score and (d) Cumulative neurological disability, were significantly lower in melatonin compare to PBS treated EAE mice. Data are expressed as the Mean ± SEM (n = 8–13). Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by the Tamhane test. Significance is indicated by *p < 0.0001 vs. EAE.

Back to article page